Patent · US Active

Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor

US10829492B2 · kind B2 · utility

0Cited by

0References

20Claims

0Family size

Assignees

Inventors

Li Zhu · Shanghai, CN
Yuandong Hu · Beijing, CN
Wei Wu · Qingdao, CN
Liguang Dai · Beijing, CN
Xiaowei Duan · Beijing, CN
Yanqing Yang · Beijing, CN
Yinghui Sun · Beijing, CN
Yongxin Han · Kirkland, CA
Yong Peng · Beijing, CN
Fansheng Kong · Beijing, CN
Hong Luo · Clemson, US
Ling Yang · Lianyungang, CN
Hongjiang Xu · Lianyungang, CN
Meng Guo · Shanghai, CN
Zhaobai Zhong · Lianyungang, CN
Shanchun Wang · 安丰镇, CN

Key dates

Filing date	Oct 27, 2017
Grant date	Nov 10, 2020
Priority date	—
Expiry date	Oct 27, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.